Related Experiment Video
Updated: Jul 6, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients
Gregg W Stone1, David J Moliterno, Michel Bertrand
1Cardiovascular Research Foundation, Lenox Hill Heart and Vascular Institute, New York, NY 10022, USA. gstone@crf.org
Abciximab reduced myocardial infarction in acute coronary syndromes (ACS) patients undergoing stenting, while tirofiban showed a trend toward better event-free survival in stable patients. Survival rates were similar between agents for both groups.
Area of Science:
- Cardiology
- Pharmacology
- Interventional Cardiology
Background:
- Glycoprotein IIb/IIIa inhibitors reduce ischemic events post-stenting.
- Relative safety and efficacy of different agents and impact of clinical syndrome acuity are not well-established.
Purpose of the Study:
- Compare abciximab and tirofiban in patients undergoing planned stenting.
- Investigate the influence of acute coronary syndromes (ACS) on treatment response.
Main Methods:
- Prospective, multicenter, double-blind, randomized trial.
- 4809 patients randomized to abciximab or tirofiban.
- Stratified analysis based on ACS presence.
Main Results:
- In ACS patients, abciximab showed lower 30-day and 6-month myocardial infarction rates (P=0.004, P=0.013).
- In non-ACS patients, tirofiban demonstrated a trend toward enhanced 6-month event-free survival (P=0.056) and reduced target vessel revascularization.
- 6-month mortality rates were identical in both groups.
Conclusions:
- Abciximab suppressed periprocedural myonecrosis more effectively in ACS patients, but without a demonstrated survival benefit.
- Tirofiban may offer equivalent or better outcomes in stable coronary syndromes with fewer adverse events.
- Data highlight the need to consider clinical scenarios for optimal glycoprotein IIb/IIIa inhibitor use and cost-effectiveness.
Related Concept Videos
Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Therapeutic Drug Monitoring: Affecting Factors
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Acute Coronary Syndrome III: Diagnostic Studies
